HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $10.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 96.85% from the company’s current price.

Other research analysts have also recently issued research reports about the company. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Leerink Partners boosted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $8.83.

Aquestive Therapeutics Stock Up 0.2 %

Shares of NASDAQ:AQST opened at $5.08 on Wednesday. Aquestive Therapeutics has a 12-month low of $1.55 and a 12-month high of $6.23. The business’s 50 day moving average is $4.92 and its 200 day moving average is $3.84.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same quarter last year, the firm posted ($0.03) earnings per share. Analysts forecast that Aquestive Therapeutics will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP lifted its position in shares of Aquestive Therapeutics by 525.5% during the 3rd quarter. GSA Capital Partners LLP now owns 137,151 shares of the company’s stock valued at $683,000 after buying an additional 115,223 shares during the last quarter. Chartwell Investment Partners LLC bought a new stake in shares of Aquestive Therapeutics during the 3rd quarter valued at $535,000. Cahill Wealth Management LLC increased its stake in Aquestive Therapeutics by 20.6% in the 3rd quarter. Cahill Wealth Management LLC now owns 142,941 shares of the company’s stock worth $712,000 after acquiring an additional 24,380 shares during the last quarter. Harvey Capital Management Inc. bought a new position in Aquestive Therapeutics in the 3rd quarter worth about $88,000. Finally, Janney Montgomery Scott LLC increased its stake in Aquestive Therapeutics by 4.9% in the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock worth $4,598,000 after acquiring an additional 42,800 shares during the last quarter. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.